Venus Medtech (Hangzhou) Inc. (Venus Medtech-B) disclosed its monthly return for July 2026, confirming that the company’s equity structure remained unchanged during the period.

Authorised and Issued Share Capital • Total authorised/registered share capital stood at RMB 441.01 million, comprising 441.01 million H shares listed in Hong Kong and 1,208 unlisted foreign shares. • Issued share capital was unchanged at 441.01 million H shares and 1,208 unlisted foreign shares; no treasury shares were held.

Public-Float Status • The company affirmed compliance with the Main Board’s minimum 25 % public-float requirement as at 31 July 2026.

Share Option Scheme • No options were outstanding or exercised during the month. • The approved scheme still allows for the future issuance of up to 44.10 million shares, representing 10 % of the existing H-share base.

Treasury and Repurchased Shares • No new repurchases occurred in July. • A previously repurchased tranche of 3.11 million H shares from December 2021 remains pending cancellation; the figure was unchanged during the month.

Other Instruments • The company reported no warrants, convertibles, or other agreements that could dilute equity.

Overall, Venus Medtech-B closed July with a stable capital base, no dilution events, and ongoing adherence to Hong Kong listing requirements.